J&J says its single dose protects against breakthrough Covid-19 for up to 6 months

The study, sponsored by the vaccine developer, was conducted between Jan 1 and Sept 7 last year, before the Omicron variant was discovered.

Reuters

January 7, 2022 1:56 AM1 minute read

J&J says protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna. Photo: Reuters

- Advertisement -

Just In

Loke's grand plan for Subang Airport expansion risks a crash landing

March 13, 2025 3:38 AM

A tale of Ramadan dates

March 12, 2025 1:58 AM

'No more excuses', Latheefa tells government, MACC as she reveals 'full, unedited' Sabah bribery videos

March 11, 2025 3:43 AM

'Anwar lying', Mahathir warns URA will marginalise poor Malay landowners in cities

March 10, 2025 7:48 AM

In Seremban, 'poorest of poor' tenants flee flats as city council breaks down doors

March 6, 2025 3:59 AM

Johnson & Johnson said on Thursday that a real-world study showed its single shot Covid-19 vaccine protects against breakthrough infections and hospitalisations for up to six months.

The study, sponsored by the vaccine developer, was conducted between Jan 1 and Sept 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.

J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech’s as well as Moderna.

No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.